Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
As we mentioned on our list of the top 30 venture capital firms of 2013, VC is part of what makes new biotechs and biopharmas blossom. Although our list is over three pages long and there seem to be an abundance of VC firms funding biopharma startups, have you ever had any problems getting capital for one of your ventures?